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Background: Perioperative pain management has recently been revolutionized with the recognition of novel
mechanisms and introduction of newer drugs. Many randomized trials have studied the use of the gabapentinoid
anti-epileptic, pregabalin, in acute pain. Published systematic reviews suggest that using pregabalin for
perioperative pain management may decrease analgesic requirements and pain scores, at the expense of
troublesome side effects. A major limitation of the extant reviews is the lack of rigorous investigation of clinical
characteristics that would maximize the benefit harms ratio in favor of surgical patients. We posit that effects of
pregabalin for perioperative pain management vary by the type of surgical pain model and propose this systematic
review protocol to update previous systematic reviews and investigate the heterogeneity in findings across
subgroups of surgical pain models.
Methods/Design: Using a peer-reviewed search strategy, we will search key databases for clinical trials on
perioperative pregabalin use in adults. The electronic searches will be supplemented by scanning the reference lists
of included studies. No limits of language, country or year will be imposed. Outcomes will include pain; use of
co-analgesia, particularly opioids; enhanced recovery; and drug-related harms. We will focus on the identification of
surgical models and patient characteristics that have shown benefit and adverse effects from pregabalin.
Two clinical experts will independently screen the studies for inclusion using eligibility criteria established a priori.
Data extracted by the reviewers will then be verified. Publication bias will be assessed, as will risk of bias using the
Cochrane Risk of Bias tool. Meta-analysis and meta-regression are planned if the studies are deemed statistically,
methodologically and clinically homogenous. Evidence will be graded for its strength for a select number of
outcomes.
Discussion: We will explore the findings of perioperative clinical trials studying the use of pregabalin for acute
pain. We will comment on the implications of the findings and provide further direction for the appropriate use of
pregabalin in acute pain. This protocol will attempt to bridge the growing gap between clinical experience and
emerging evidence, and has the potential to aid future guideline development in the perioperative use of
pregabalin.
Trial registration: PROSPERO registration number CRD42012002078
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Pregabalin is a well-recognized central nervous system
depressant that was first introduced in 2004 as an epi-
leptic and more potent successor to gabapentin [1].
Though gabapentin was also initially approved for treat-
ing seizures, it found widespread use in the treatment of
chronic pain, and this was followed by a number of clin-
ical trials reporting benefits with gabapentin in acute
postoperative pain. Pregabalin has almost followed gaba-
pentin on this path of clinical utilization - currently the
United States Food and Drug Administration (FDA) and
Health Canada approve the use of pregabalin for seizures
and chronic pain (post herpetic neuralgia, fibromyalgia
and diabetic peripheral neuropathy) [1]. In the European
Union, pregabalin is also approved for use in generalized
anxiety disorders [2]. Therefore the use of the gabapenti-
noids (gabapentin and pregabalin) for acute postopera-
tive pain, though widely reported, is still off-label. The
off-label use of gabapentin has been controversial and
subject to a large financial settlement by industry for il-
legal and fraudulent promotion of unapproved uses [3].
The gabapentinoids are unique in their mechanism of
action, which also explains most of their clinically rele-
vant pharmacology. They bind to the alpha2delta sub-
unit of the voltage-gated calcium channel in the central
nervous system and this decreases the release of a var-
iety of neurotransmitters. While their primary use con-
tinues as potent anti-epileptics and in chronic pain, their
emerging role as anti-hyperalgesics has been of use in
perioperative pain management. Other investigators
have suggested that the anxiolytic, sedative and sleep re-
storative properties of these drugs may additionally
benefit patients with pain.
There is well-documented evidence and extensive ex-
perience with gabapentinoids in perioperative pain man-
agement [4]. Similar clinical benefit has been reported
with pregabalin; when compared with gabapentin, prega-
balin has greater potency, better bioavailability and fewer
side effects [5]. Clinical trials with pregabalin in peri-
operative pain followed the anecdotal and observational
evidence that suggested its usefulness in treating acute
neuropathic symptoms and indicated an apparent
opioid-sparing effect [5]. As such, the off-label use of
pregabalin in the perioperative period for acute pain has
continued to be investigated and reported. The focus of
perioperative pain management has shifted from just
treating the pain to wider enhanced recovery programs
(early ambulation, early feeding and shortened length of
stay), fewer side effects and some long-term benefits.
This wider impact of pregabalin in enhanced recovery
programs and for reduced incidence of chronic postsur-
gical pain continues to be evaluated.
In 2009, a Cochrane systematic review evaluated
the available evidence for acute and chronic painmanagement with pregabalin. Six perioperative clinical
trials were included for analysis and these authors con-
cluded that there is no evidence to support the use of
pregabalin in acute pain [6]. Further accumulating evi-
dence was reported in the next meta-analysis by Zhang
and colleagues in 2010 that included 11 randomized
controlled trials (RCTs) [7]. They reported that, though
pregabalin did not reduce postoperative pain scores, it
reduced opioid consumption and opioid-related adverse
effects after surgery. In 2011, as perioperative clinical
trials in pregabalin continued to be reported, Engelman
and Cateloy published their meta-analysis of 18 RCTs on
the use of pregabalin for acute pain [8]. They reported
that pregabalin increased the risk of dizziness, light-
headedness and visual disturbances, but decreased the
occurrence of postoperative nausea and vomiting
(PONV) in patients who did not receive anti-PONV
prophylaxis. They concluded that, in the postoperative
period, pregabalin provides additional analgesia but at
the cost of additional adverse effects.
Our clinical experience with this drug has been exten-
sive and we have previously published a clinical algo-
rithm guiding appropriate patient and surgical
procedure selection to maximize the benefit and
minimize harms of perioperative pregabalin in acute
pain management [9]. In our experience, patients with
preoperative chronic pain, having surgery at the site of
pain, or having otherwise painful surgical procedures
benefit most from perioperative use of pregabalin. Rele-
vant populations could include those undergoing spinal
surgery, amputations and joint replacement, or others
with higher prevalence of chronic postsurgical pain (for
example, breast surgery and dental extractions). The bal-
ance of benefit to harm is likely to be unfavorable for
patients undergoing procedures that are not painful or
are not associated with chronic pain (for example, chole-
cystectomy or laparoscopic gynecological procedures).
Our algorithm also points out that side effects with
pregabalin (somnolence, sedation, visual disturbances,
confusion and respiratory depression) may be more
common in the elderly, in patients with sleep apnea and
in those with renal function impairment [9].
Since the last meta-analysis by Engelman and Cateloy
[8], a significant number of RCTs on the perioperative
use of pregabalin for acute pain have been published.
With the emergence of new evidence, and our clinical
hypothesis that the balance of benefit versus harm of
pregabalin use might favor only a subset of patients
undergoing certain surgical procedures, a systematic re-
view of the literature is warranted. For appropriate clin-
ical decision-making, and possibly to provide an
evidence basis for future clinical practice guidelines on
the perioperative use of pregabalin for pain control, our
proposed review will primarily focus on an exploration
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harms across the clinical and methodological diversity
observed in the extant literature.
Aims and objectives
The aim of this systematic review is to evaluate the ef-
fectiveness and harms of perioperative pregabalin in the
management of postoperative pain for the diverse
patients undergoing various surgical procedures. To this
end, the proposed systematic review will answer the fol-
lowing questions:
1. When compared with standard multimodal analgesia,
what are the comparative effectiveness and harms of
the co-administration of pregabalin in the
perioperative pain management of adult patients?
2. Is there a definitive opioid-sparing advantage of
pregabalin (for example, lower risk of nausea,
vomiting, somnolence, opioid use, and other opioid-
related side effects) when used for perioperative pain
management in adults?
3. For questions 1 and 2 above, what clinical and study
methodological characteristics explain the
heterogeneity in results?
Methods/Design
The conduct of our systematic review will comply with
the methodological standards outlined in the Cochrane
Handbook for Systematic Reviews of Interventions, and
methods papers published for the Effective Healthcare
Program of the Agency for Healthcare Research and
Quality [10-12]. Reporting of our review findings will
adhere to the standards for the Preferred Reporting
Items for Systematic reviews and Meta-Analyses [13]. Our
review has been prospectively registered (CRD42012002078)
with the International Prospective Register of Systematic
Reviews (PROSPERO [14]).
Eligibility criteria
Table 1 lists our study eligibility criteria. We will include
studies published in the English language; however, our
search of the literature will not be restricted by language
of publication. As such, we will report the number of
studies excluded because of language ineligibility. Stud-
ies will not be excluded based on publication status,
publication date or reported outcomes. As an adequate
body of evidence from RCTs is anticipated, our review
will exclude all non-randomized study designs.
Information sources and literature search
Electronic search strategies will be developed and tested
by an experienced medical information specialist in con-
sultation with the Evidence based Practice Center (EPC)
team. The search strategy will be peer-reviewedaccording to the peer review of electronic search strat-
egies guideline [15]. Published literature will be identi-
fied through searching MEDLINE, EMBASE (via OVID)
and the Cochrane Central Register of Controlled Trials
database (via OVID). The strategy for MEDLINE is
included as Additional file 1: Appendix 1 and will be
translated as appropriate for the other databases. The
search strategies will combine the use of controlled vo-
cabulary and keywords. There will be no language or
date restrictions. Animal studies will be excluded. The
study design filter will be used to identify RCTs. For MED-
LINE, the Cochrane Highly Sensitive Search Strategy for
identifying randomized trials in MEDLINE sensitivity-
maximizing version (2008 revision) and the OVID format
will be used.
Additional references will be sought through scanning
the reference list of systematic reviews on pregabalin for
acute pain in the perioperative setting.
Study selection process
Two reviewers will independently screen all identified
items at two levels. Level 1 screening will entail a
broad screen based on item titles and/or abstracts, as
available. The full-text of all items passing Level 1
screening will be retrieved for Level 2 screening: an as-
certainment of final eligibility for the review. Discrep-
ancies will be resolved by consensus or by involving a
third team member. All screening will be conducted in
DistillerSR (Evidence Partners Incorporated, Ottawa,
Canada) using inclusion criteria developed a priori as
described above.
Data items and data collection process
Standardized data extraction forms, with accompanying
data extraction guidelines, will be iteratively developed
and pilot tested until an appropriate level of consensus
is reached. Data will be extracted by one reviewer and
verified by another. Errors in data abstraction will be
corrected after consultation with the primary data ex-
tractor, as required. Authors of studies may be contacted
for missing data or data clarification. Multiple publica-
tions of the same study will be identified and used for all
relevant reported data. The multiple publications then
will be linked together as companion reports, but true
duplicates will be excluded.
For all studies, the following data will be extracted:
 Study characteristics: first author; year of
publication; country of origin; funding source; study
design and setting; duration of follow-up; number
randomized; number analyzed for each outcome;
and number of drop-outs with reason.
 Population characteristics: inclusion and exclusion
criteria; patient characteristics (for example, age,
Table 1 Review eligibility criteria
Study characteristic Inclusion criteria Exclusion criteria
Patient population • Adults undergoing elective surgical procedures • Non-surgical use, such as anti-epileptic,
chronic pain, psychiatric conditions,
generalized anxiety disorder
• Trauma, burns without surgery
• Other painful medical conditions, such
as diabetic peripheral neuropathy,
post herpetic neuralgia, fibromyalgia
Intervention- Treatment • Oral pregabalin (any dose) administered before
and/or after surgery with or without background
multimodal analgesia
• Gabapentin
• Studies of pregabalin in combination with another drug
will also be included but excluded in sensitivity analyses
Intervention- Comparison • Placebo or any specific analgesic (including pregabalin in a
different dose or gabapentin) with any route of administration,
except sedatives and hypnotics (for example, acetaminophen,
nonsteroidal anti-inflammatory drugs, opioids, tricyclic antidepressants)
• Comparators may or may not have been added on to background
multimodal analgesia.






Setting • Inpatient with or without extension to outpatient settings • Exclusively outpatient
Timing • 48 to 24 hours before surgery to 7 days (for acute pain) and up
to 6 months postsurgery (for chronic postoperative pain)
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co-morbidities (for example, kidney disease, sleep
apnea); type and duration of elective surgery;
anesthesia protocol (general, spinal or regional);
anatomical site of surgery; pre-existing pain at the
site of surgery; history of use of gabapentinoids in
the last 6 months; history of past surgery at same
anatomical site or a different site of surgery; and
history of opioid abuse and dependence.
 Intervention characteristics: dose, frequency, timing
and duration of treatment; drug compliance;
co-interventions (co-analgesia with dose, frequency
and duration); and concomitant medications (dose,
frequency and duration).
 Comparison intervention characteristics:
intervention description, dose, duration of
treatment.
 Outcomes: In addition to quantitative data for each
of the following outcomes (Table 2), details of their
definitions, cut-offs used for categorizations, and
tools of measurements will also be extracted. Where
possible, data will be extracted as number of
patients with an event (as opposed to number of
events) to ensure only one event is recorded perpatient in cases of multiple events experienced by
the same patient.
Risk of bias appraisal
We will use the Cochrane Risk of Bias tool in parallel to
the Jadad tool to evaluate the internal validity of the de-
sign and conduct of included studies [16]. Blinding of
participants, healthcare providers, and outcome asses-
sors will be judged as low risk for objective outcomes
such as mortality.
For harms outcomes, additional criteria will include
precise definitions, mode of data collection (active evalu-
ation versus passive reporting), and type of harms
analysis.
For the gradable outcomes (see below), we will evalu-
ate the risk of publication bias for the body of evidence
when all of the following criteria are met:
 ≥ 10 studies contributing data for an outcome
 studies of unequal sizes
 no substantial clinical and methodological
differences between smaller and larger studies
 quantitative results accompanied with measures of
dispersion.
Table 2 Review outcomes
Type of outcome Outcome
Primary perioperative efficacy outcomes • Pain relief at rest and on movement (any measure)
• Reduction in postoperative opioid and other analgesic consumption
(dose, frequency, and time of first use of rescue analgesia)





• Length of hospital stay
• Chronic postoperative pain






• Withdrawal due to adverse events
• Participants with at least one serious adverse event (as defined by the FDA)
• Mortality
• Participants with at least one adverse event
• Withdrawal due to lack of pregabalin efficacy
FDA: Food and Drugs Administration
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Our primary outcomes are pain relief at rest and on
movement (any measure) and reduction in postoperative
opioid and other analgesic consumption. Other out-
comes of interest are pre-specified above. We will first
report our results descriptively and narratively.
Because exploration of subgroup differences in the
effects of pregabalin is of main import, main analyses
will be directed towards the following surgical pain mod-
els: surgery associated with severe neuropathic pain (for
example, spine surgeries, joint replacement and amputa-
tions); surgery associated with chronic postsurgical pain
(for example, breast surgery, hernia repair and spine sur-
geries); and unclassified.
We will also attempt to investigate an overall relative
drug effect for outcomes across all patient populations,
co-analgesia, and types of surgical models when there is
no major inconsistency in effect estimates or when het-
erogeneity across studies cannot be explained by clinical
and methodological factors. As a rule, heterogeneity that
can be explained by differences amongst the studies will
preclude any planned meta-analyses. All meta-analyses
will be based on the DerSimonian’s and Laird’s random
effects approach [17]. Statistical heterogeneity between
studies will be quantified with I-squared statistics andthe P value from the chi-squared test (P ≤ 0.10 instead
of ≤ 0.05 will be used to determine statistical signifi-
cance). Sparse data will not be meta-analyzed but
described narratively.
It is anticipated that outcomes may be reported as di-
chotomous, continuous or count data. Relative risk for
dichotomous outcomes, mean difference or standardized
mean differences for continuous, and rate ratios for
count data will be preferred measures of analysis. Studies
with zero events in one arm will be meta-analyzed with-
out continuity correction with either the Peto method or
the Mantel-Haenszel method [11,17]. Studies with zero
events in both arms will be excluded from meta-
analyses.
Meta-regression with multiple study level covariates
will be attempted when there are at least 10 studies in a
meta-analysis. Otherwise, clinical and methodological di-
versity in studies will be explored in subgroup analysis
for the following study level covariates, data permitting:
Methodological covariates - study risk of bias and
short- and longer-term perioperative period.
Clinical covariates - surgery at the site of chronic pain
and surgery away from the site of chronic pain; patients
with opioid dependence or tolerance, anxiety, sleep
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preoperative pain and patients without preoperative
pain; single preoperative dose of pregabalin, multiple
doses of pregabalin, and various doses of pregabalin
(low dose < 150 mg/day, intermediate dose 150 to
300 mg/day and high dose > 300 mg/day); various types
of surgeries; studies on patients likely to experience
chronic postoperative pain; and subtypes of anesthesia
protocols (general, spinal or regional).
Grading the strength of evidence and assessment of
applicability
For a given outcome, reviewers’ confidence on the body
of evidence in support of a conclusion will be graded as
per previous guidance [12]. Mandatory domains that will
be assessed will include Risk of Bias, Consistency, Dir-
ectness and Precision. Our pre-specified gradable out-
comes are outcomes most likely to influence decision-
making. They include: mortality, serious adverse events,
respiratory depression or arrest, visual disturbances, pain
relief or scores, analgesic consumption, sleep restoration,
and enhanced recovery (early feeding and ambulation,
and length of hospital stay). For the body of evidence,
we will summarize the population, intervention, com-
parator, setting and study duration data that may be
used to assess external validity of evidence by various
stakeholders and decision-makers.
Discussion
The gabapentinoids, pregabalin and gabapentin, are novel
drugs that have probably revolutionized the management
of pain [1]. Both drugs share similar anti-hyperalgesic,
sedative and anxiolytic properties and are currently ap-
proved for use in chronic pain. Since its introduction into
clinical practice in 2004, pregabalin has demonstrated
the more favorable pharmacokinetic profile, especially
a more predictable dose-independent absorption. This
property and its improved side-effect profile make prega-
balin highly desirable for the management of periopera-
tive pain.
It is important to appreciate this evolution in the clin-
ical use of the gabapentinoids, as other systematic
reviews have provided combined analyses of gabapentin
and pregabalin for either or both chronic and acute pain
[5,18,19]. Our systematic review will focus on the use of
pregabalin for acute pain.
The first narrative review published by Gajraj in De-
cember 2007 on the use of pregabalin suggested that it
would be useful for acute pain and predicted that it
would likely become well studied as part of multimodal
analgesia [1]. The Cochrane review in 2009, however,
suggested that there was no benefit in acute pain from
pregabalin, which was not surprising because the evi-
dence available was limited [6]. As more clinical trialswere performed and their findings became available, sys-
tematic reviews reported that pregabalin decreased pain
scores, analgesic consumption and side effects [7,8].
There was also suggestion that some indirect peri-
operative benefit from pregabalin resulted in decreas-
ing analgesic (opioid) consumption, thereby decreasing
nausea and vomiting, the well-known side effects of
opioids [8]. The limitations of the previous meta-
analysis include the wide variability of the studies, the
pregabalin dose and regimes, and the anesthetic and
analgesic protocols, as well as an inability to pool data
due to heterogeneity [7].
We determined that the findings of these systematic
reviews are not consistent across all patients or all surgi-
cal procedures. We have previously identified patient
characteristics and surgical procedures that may benefit
from pregabalin [9]. Through this systematic review, we
would like to carefully explore the findings of the more
recent perioperative clinical trials that have studied the
use of pregabalin for acute pain. We will comment on
the implications of the findings and provide further dir-
ection for the appropriate use of pregabalin in acute
pain. This protocol will attempt to bridge the growing
gap between clinical practice and emerging evidence. Fi-
nally, this systematic review has the potential to aid fu-
ture guideline development in the perioperative use of
pregabalin.
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